GET DAILY SIGNALSWhy Is Doximity (DOCS) Stock Down -3.65% Today?
Key Takeaways
- Doximity (DOCS) shares are trading down roughly -3.65%, to about $31.97, versus a prior-session close of $33.18.
- The decline extends a sharp post-earnings selloff that began in after-hours trading following the company's fiscal 2027 second-quarter report.
- Investors are reacting to decelerating revenue growth and compressed margins, even as the headline results modestly beat estimates.
- Guidance was raised, but retention metrics weakened and the company signaled a gradual AI revenue ramp, pressuring sentiment.
- The move is largely company-specific, diverging from a relatively steady broader market backdrop.
- Traders are watching for analyst target revisions, the pending legal overhang, and the next earnings catalyst.
- For more detail on Price Targets, Earnings, and Forecast, explore Doximity's dedicated pages.
- Interested in automated strategies? Browse Trending AI Robots to see which AI-driven trading bots are leading under current market conditions.
Opening Summary
Doximity, Inc. (DOCS) is a digital platform and network serving U.S. medical professionals, offering a newsfeed, communication tools, and a growing suite of AI-powered clinical and workflow products. Shares of the company are under pressure in today's session, trading down roughly 3.65% to about $31.97, compared with a prior-session closing price of $33.18. The decline is a continuation of a post-earnings reaction: the company reported fiscal second-quarter results after the previous close, and despite a modest beat on the top and bottom lines, investors focused on slowing growth, shrinking profitability, and softer retention metrics.
Earnings Results and the Margin Squeeze
The primary catalyst behind the move is Doximity's fiscal 2027 second-quarter earnings report. Revenue rose about 3.6% year over year to $174.5 million, and non-GAAP earnings per share came in at $0.36, slightly ahead of consensus estimates near $0.35. On the surface, that reads as a beat — yet the market's reaction has been decisively negative.
The core concern is profitability. Adjusted EBITDA fell roughly 12% year over year to about $88.9 million, and the adjusted EBITDA margin compressed to around 51% from roughly 60% a year earlier. On a GAAP basis, net income nearly halved, and non-GAAP gross margin slipped as the company invested heavily in AI compute. The picture is one of a company trading near-term margin for an AI buildout — a trade-off that Wall Street has been quick to question.
Decelerating Growth and Weakening Retention
Beyond margins, investors are scrutinizing the trajectory of the business. Revenue growth of about 3.6% marked a clear deceleration from roughly 7% in the prior quarter, which management attributed in part to a difficult comparison. Retention metrics also deteriorated: net revenue retention reportedly fell to about 103% from 107% in the prior quarter, and retention among the largest customers softened as well.
While management pointed to accelerating adoption of its AI products — including growth in AI Search bookings, active prescribers, and health systems adopting the AI suite — the ramp is expected to be gradual through calendar 2027. That gradual timeline has left investors less willing to pay a premium for a reacceleration story that has yet to fully materialize in the numbers.
Guidance and the Market Reaction
The company raised its fiscal 2027 revenue outlook to a range of $678 million to $683 million and guided third-quarter revenue to roughly $195 million to $196 million. However, some sell-side estimates had already been positioned at the higher end, leaving limited room for the kind of upward revision that typically supports a stock after a print. The combination of in-line results, margin pressure, and a modestly conservative outlook drove shares lower in after-hours trading, and that weakness has carried into today's session.
Market Context and Trading Activity
Doximity's decline appears largely company-specific rather than a broad-market or sector-driven move. The stock's reaction diverges from a relatively steady backdrop in major indices, underscoring that investors are pricing in concerns unique to Doximity's growth and margin profile. The shares have been volatile around earnings in the past, with outsized single-session moves in both directions, and today's action reflects the market digesting the latest quarterly data rather than any single macro catalyst. From a technical standpoint, the stock traded near its recent lows intraday, testing areas below the prior session's close that traders are watching closely.
What Comes Next for DOCS
Looking ahead, investors will be focused on whether Doximity can deliver the reacceleration that management has signaled. Key watchpoints include the pace of AI Search bookings converting to revenue, whether retention metrics stabilize, and whether margin pressure moderates as the AI cost structure scales. The company also faces a pending legal overhang, including securities class-action filings, and analyst expectations remain wide-ranging. With the next earnings report still months away and consensus estimates having shifted over the past year, near-term sentiment is likely to hinge on analyst revisions and any further updates on AI adoption and customer retention.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are currently demonstrating the strongest performance under prevailing market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and the symbols it trades. The featured section surfaces only the top performers, helping traders discover automated strategies that are adapting to today's environment. Explore the Trending AI Robots page to see which strategies are leading right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
DOCS sees MACD Histogram just turned negative
DOCS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 30, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 36 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for DOCS moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 21 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 56 cases where DOCS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DOCS as a result. In 59 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DOCS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
DOCS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The 50-day moving average for DOCS moved above the 200-day moving average on October 14, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +3.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where DOCS advanced for three days, in 210 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 123 of 178 cases where DOCS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. DOCS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.456) is normal, around the industry mean (4.793). P/E Ratio (36.867) is within average values for comparable stocks, (13.685). Projected Growth (PEG Ratio) (0.590) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (7.776) is also within normal values, averaging (6.065).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DOCS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement